Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Maze Therapeutics (MAZE) Receivables - Other (2025 - 2026)

Maze Therapeutics' Receivables - Other history spans 2 years, with the latest figure at $1.8 million for Q1 2026.

  • On a quarterly basis, Receivables - Other changed N/A to $1.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.8 million, a N/A change, with the full-year FY2025 number at $1.5 million, changed N/A from a year prior.
  • Receivables - Other hit $1.8 million in Q1 2026 for Maze Therapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Receivables - Other for MAZE hit a ceiling of $1.8 million in Q1 2026 and a floor of $700000.0 in Q3 2025.